B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
Bof A證券將Novavax上調至中性,將目標股價上調至12美元
B of A Securities analyst Alec Stranahan upgrades Novavax (NASDAQ:NVAX) from Underperform to Neutral and raises the price target from $4 to $12.
B of A Securities分析師亞歷克·斯特拉納漢將Novavax(納斯達克股票代碼:NVAX)從表現不佳上調至中性,並將目標股價從4美元上調至12美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。